All In Biotech

Drug Trial Radar · NCT06673238

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Oct 29, 2024

Primary completion

Jun 25, 2026

Study completion Jun 25, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-722Drug

    Oral Capsule

  • PlaceboDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events Reported During Safety EvaluationsTime frame: Up to Day 44
  2. Maximum Plasma Concentration (Cmax) of ABBV-722Time frame: Up to Day 21
  3. Time to Cmax (Tmax) of ABBV-722Time frame: Up to Day 21
  4. For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722Time frame: Up to Day 8
  5. For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722Time frame: Up to Day 8
  6. For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722Time frame: Up to Day 21
  7. For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722Time frame: Up to Day 21
  8. Terminal Phase Elimination Rate Constant (Beta) of ABBV-722Time frame: Up to Day 21
  9. Terminal Phase Elimination Half-Life (t1/2) of ABBV-722Time frame: Up to Day 21
  10. Dose Normalized CmaxTime frame: Up to Day 21
  11. Dose Normalized AUCsTime frame: Up to Day 21

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical Los Angeles /ID# 280183

    Cypress, California

  • Acpru /Id# 270279

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.